Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

  • Cao, Fang (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) ;
  • Wang, Kuo (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) ;
  • Zhu, Rong (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) ;
  • Hu, Yong-Wei (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) ;
  • Fang, Wen-Zheng (Department of Oncology Fuzhou General Hospital of Nanjing Command) ;
  • Ding, Hou-Zhong (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University)
  • Published : 2013.01.31


Secreted protein acidic and rich in cysteines-like protein 1 (SPARCL1), an extracellular matrix glycoprotein, has been implicated in the pathogenesis of several disorders including cancer. However, little is known about the expression and significance of SPARCL1 in human breast cancer. The aim of this study was to determine the expression pattern and clinicopathological significance of SPARCL1 in a Chinese breast cancer cohort. mRNA and protein expression of SPARCL1 in human breast cancer cell lines and breast cancer tissues was detected using the reverse transcription-polymerase chain reaction, real-time quantitative PCR, and Western blotting, respectively. Immunostaining of SPARCL1 in 282 Chinese breast cancer samples was examined and associations with clinicopathological parameters were analyzed. Compared to the positive expression in immortalized human breast epithelial cells, SPARCL1 was nearly absent in human breast cancer cell lines. Similarly, a significantly reduced expression of SPARCL1 was observed in human breast cancer tissues compared to that in normal breast epithelial tissues, for both mRNA and protein levels (P < 0.001). Immunohistochemical analysis showed that strong cytoplasmic immunostaining of SPARCL1 was observed in almost all normal breast samples (43/45) while moderate and strong immunostaining of SPARCL1 was only detected in 191 of 282 (67.7%) breast cancer cases. Moreover, down-regulation of SPARCL1 was significantly correlated with lymphatic metastasis (P = 0.020) and poor grade (P = 0.044). In conclusion, SPARCL1 may be involved in the breast tumorigenesis and serve as a promising target for therapy of breast cancer.


  1. Rosman DS, Kaklamani V, Pasche B (2007). New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol, 8, 61-73.
  2. Russo J, Calaf G, Sohi N, et al (1993). Critical steps in breast carcinogenesis. Ann N Y Acad Sci, 698, 1-20.
  3. Shen FR, Liu M, Zhang X, et al (2012). Health-related quality of life among breast cancer patients and its Influencing Factor in a Chinese Population. Asian Pac J Cancer Prev, 13, 3747-50.
  4. St Croix B, Rago C, Velculescu V, et al (2000). Genes expressed in human tumor endothelium. Science, 289, 1197-202.
  5. Sullivan MM, Sage EH (2004). Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol, 36, 991-6.
  6. Zhang H, Widegren E, Wang DW, Sun XF (2011). SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer. Tumour Biol, 32, 1225-31.
  7. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA (2011). Identification of common differentially expressed genes in urinary bladder cancer. PLoS One, 6, e18135.
  8. Isler SG, Schenk S, Bendik I, et al (2001). Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol, 18, 521-6.
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  10. Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001). Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet, 10, 657-62.
  11. Kataja V, Castiglione M, ESMO Guidelines Working Group (2008). Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 19, ii11-3.
  12. Kononen J, Bubendorf L, Kallioniemi A, et al (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4, 844-7.
  13. Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST (2006). SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol, 210, 459-68.
  14. Li P, Qian J, Yu G, et al (2012). Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol, 105, 31-7.
  15. Long N, Moore MA, Chen W, et al (2010). Cancer epidemiology and control in north-East Asia - past, present and future. Asian Pac J Cancer Prev, 11 suppl 2, 107-48.
  16. Mencalha AL, Levinsphul A, Deterling LC, Pizzatti L, Abdelhay E (2008). SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Mol Med Report, 1, 571-4.
  17. Nelson PS, Plymate SR, Wang K, et al (1998). Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res, 58, 232-6.
  18. Bendik I, Schraml P, Ludwig CU (1998). Characterization of MAST9/Hevin, a SPARC-like protein, that is downregulated in non-small cell lung cancer. Cancer Res, 58, 626-9.
  19. Claeskens A, Ongenae N, Neefs JM, et al (2000). Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer, 82, 1123-30.
  20. Eheman C, Henley SJ, Ballard-Barbash R, et al (2012). Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer, 118, 2338-66.
  21. Esposito I, Kayed H, Keleg S, et al (2007). Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia, 9, 8-17.
  22. Girard JP, Springer TA (1995). Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity, 2, 113-23.
  23. Girard JP, Springer TA (1996). Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem, 271, 4511-7.
  24. Hambrock HO, Nitsche DP, Hansen U, et al (2003). SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem, 278, 11351-8.
  25. Hu H, Zhang H, Ge W, et al (2012). Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res, 18, 5438-48.
  26. Hulvat MC, Hansen NM, Jeruss JS (2009). Multidisciplinary care for patients with breast cancer. Surg Clin North Am, 89, 133-76, ix.
  27. Hurley PJ, Marchionni L, Simons BW, et al (2012). Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci USA, 109, 14977-82.
  28. Isler SG, Ludwig CU, Chiquet-Ehrismann R, Schenk S (2004). Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors. Int J Oncol, 25, 1073-9.

Cited by

  1. Update December 2013 vol.11, pp.4, 2013,
  2. Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling vol.9, pp.10, 2014,
  3. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma vol.37, pp.3, 2016,
  4. Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells vol.13, pp.5, 2017,
  5. Robust identification of target genes and outliers in triple-negative breast cancer data pp.1477-0334, 2018,
  6. Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors vol.18, pp.1, 2018,
  7. Multi-platform analysis of methylation-regulated genes in human lung adenocarcinoma vol.82, pp.1, 2019,